Get the Stockscreener App
1.24
2.36%
-0.03
Inmune Bio Inc stock is traded at $1.24, with a volume of 150.55K.
It is down -2.36% in the last 24 hours and down -10.79% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.27
Open:
$1.28
24h Volume:
150.55K
Relative Volume:
0.38
Market Cap:
$32.97M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-0.7317
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
-1.59%
1M Performance:
-10.79%
6M Performance:
-38.31%
1Y Performance:
-84.34%
1-Day Range:
$1.24
$1.305
1-Week Range:
$1.20
$1.305
52-Week Range:
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.24 | 32.97M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
INmune Bio reports positive Phase 2 MRI results - TipRanks
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
INMB: INmune Bio Reports Promising MRI Findings from Alzheimer's Trial - GuruFocus
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 MINDFuL Alzheimer's Trial - marketscreener.com
INmune Bio reports positive MRI results from Alzheimer’s trial - Investing.com
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial - TradingView
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - The Manila Times
Brain scans in early Alzheimer’s trial show drug affecting white matter - Stock Titan
INMB Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Amidst Pipeline ProgressEarnings Revision Upgrade - newsline.com
INmune Bio (INMB) Q4 2025 Earnings Transcript - The Globe and Mail
INmune Bio Inc. (INMB) Navigates Near Support Levels Amid Modest DeclineValue Stock Ideas - newsline.com
INmune Bio (INMB) Holds Near Support Amid Modest Decline – Key Levels in FocusWatchlist Stock Ideas - newsline.com
Inmune Bio Inc stock (US45764T1060): Short interest rose in May - AD HOC NEWS
INMB Q4 2025 Earnings: EPS Beat Surprises as Clinical-Stage Biotech Advances PipelineConsensus Miss Rate - The Legal Advocate
INmune Bio Inc. (INMB) Slips Further as Stock Tests Key Support at $1.35BPI Reversal - The Legal Advocate
INmune Bio Inc. (INMB) Holds Near Support as Biotech Stock Edges HigherTake Profit Levels - newsline.com
INMB Q4 2025 Earnings: Narrower Loss Beats Estimates, Pipeline Progress HighlightedWeak Earnings Momentum - The Legal Advocate
INMB Q4 2025 Earnings: EPS Surpasses Estimates as Loss NarrowsEarnings Stability Report - thelegaladvocate.com
INMB Q4 2025 Earnings: Narrowing Losses Amid Clinical Pipeline ProgressInterim Report - newsline.com
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline - AD HOC NEWS
INMB Stock Price, Quote & Chart | INMUNE BIO INC (NASDAQ:INMB) - ChartMill
INmune Bio (INMB) Crushes Q4 2025 Estimates — EPS $-0.20 Tops ViewsBanking Earnings Report - The Legal Advocate
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com
Inmune Bio stock (US45764T1060): Year-end 2025 results and update in focus - AD HOC NEWS
INmune Bio publishes Alzheimer’s trial results in journal - Investing.com UK
INMB Shows Promising Alzheimer's Results in MINDFuL Trial - GuruFocus
INmune Bio: Interview With Co-Founder & CEO David Moss About The Immunotherapies Company - Pulse 2.0
INmune Bio publishes Alzheimer’s trial results in journal By Investing.com - Investing.com South Africa
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - The Manila Times
Alzheimer’s drug XPro shows directionally consistent benefits, no ARIA - Stock Titan
INmune Bio Receives FDA Fast Track for XPro - TipRanks
INMB Secures Fast Track Designation for Alzheimer's Treatment - GuruFocus
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
INmune Bio receives FDA fast track status for Alzheimer’s drug - Investing.com UK
INmune Bio (INMB) Stock: Up +14.73%, Key Resistance at $1.76 2026-05-14Expert Entry Points - newser.com
INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment - Pluang
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug By Investing.com - Investing.com South Africa
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug - Investing.com Australia
INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease - marketscreener.com
INmune Bio receives FDA fast track status for Alzheimer’s drug By Investing.com - Investing.com Australia
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - The Manila Times
FDA Fast Tracks brain-inflammation drug for early Alzheimer’s - Stock Titan
INmune Bio (INMB) Q1 2026 Earnings Transcript - AOL.com
INmune Bio joins 26 companies to form American Biotech Innovation Alliance for US biotech leadership - Pluang
TradingKey - TradingKey
INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey
INMB: INmune BioInteractive Chart - Zacks Investment Research
Expanding partnership aims to advance stem cell therapy to treat RDEB - Epidermolysis Bullosa News
Q1 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
INmune Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):